Skip to search formSkip to main contentSkip to account menu

bispecific antibody 2B1

Known as: MoAb 2B1 Bispecific, 2B1 Bispecific Murine MAb, BsAb 2B1 
A monoclonal antibody with potential antineoplastic activity. Specific for both the immunoglobulin G (IgG) receptor CD16 and c-erbB-2, bispecific… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (1)

Antibodies, Bispecific
Antigens, CD16Bispecific Monoclonal AntibodiesERBB2 protein, humanNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
IntroductionThe pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different diseases… 
Highly Cited
1998
Highly Cited
1998
Peroxynitrite-mediated nitration of tyrosine and inactivation of the catalytic activity of cytochrome P450 2B1.
The addition of peroxynitrite to purified cytochrome P450 2B1 resulted in a concentration-dependent loss of the NADPH- and… 
Highly Cited
1998
Highly Cited
1998
Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
The FcR for IgA (Fc alpha RI, CD89) is primarily expressed on cytotoxic immune effector cells. By chemically cross-linking F(ab… 
Highly Cited
1997
Highly Cited
1997
Retargeting serum immunoglobulin with bispecific diabodies
Monospecific antibody fragments produced in bacteria lack the Fc portion of antibodies, and are therefore unable to recruit… 
Highly Cited
1996
Highly Cited
1996
Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide.
Cyclophosphamide is an inactive prodrug which is converted by hepatic cytochrome P450 2B1 to cytotoxic metabolites which produce… 
Highly Cited
1995
Highly Cited
1995
Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII
Abstract 2B1 is a bispecific murine monoclonal antibody (BsMAb) with specificity for the c-erbB-2 and FcγRIII extracellular… 
Highly Cited
1995
Highly Cited
1995
Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
2B1 is a bispecific murine monoclonal antibody (BsMAb) with specificity for the c-erbB-2 and Fc gamma RIII extracellular domains… 
Highly Cited
1995
Highly Cited
1995
Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Bispecific monoclonal antibodies (BsmAb) can be used to specifically target tumor cells for cytotoxicity mediated by defined… 
Highly Cited
1993
Highly Cited
1993
Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
Bispecific monoclonal antibodies (BsmAb) with specificity for tumor Ag and effector cell trigger molecules have been shown to… 
1993
1993
Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
A panel of bispecific F(ab')2 antibodies (BsAb) have been constructed for delivering the ribosome-inactivating protein saporin to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)